Gain/amplification of 1q21 is the most powerful geneticprognostic factor for patients treated by autologous stem celltransplantation
Le résumé fourni par la source
Our data suggest that gain1q21 is associated with reduced PFS and OS intervals in patients treated with autologous transplantation. Similarly a trend towards shorter survival for del17p13 positive patients was observed. Moreover, negative prognostic impact of gain1q21 can be boosted by presence of any other studied chromosomal aberration, which implicates much poorer outcome for patients carrying those aberrations together (data not shown). The treatment response of MM patients is not significantly influenced by any of the analyzed chromosomal abnormality. Presence of gain1q21 is significantly associated with presence of del(17p). Considering observation of unfavourable prognostic impact of gain1q21 either with or without correlation of any other studied aberrations, gain1q21 seems to be the most powerful independent prognostic factor for newly diagnosed MM patients treated by autologous stem cell transplantation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.